ישראל - עברית - Ministry of Health

teva pharmaceutical industries ltd, israel - losartan potassium - טבליות מצופות פילם - losartan potassium 50 mg - losartan - losartan - hypertension: losartan is indicated for the treatment of heart failure (nyha ii and iii) usually in addition to diuretics and/or digitalis if use of an ace inhibitor is not appropriate. switching patients with heart failure who are stable on an ace inhibitor to losartan is not recommended. renal protection in type-2 diabetic patients with proteinuria: losartan is indicated to delay the progression of renal disease as measured by a reduction in the combined incidence of doubling of serum creatinine end stage renal disease (need for dialysis or renal transplantation) or death and to reduce proteinuria. reduction in the risk of cardiovascular morbidity and mortality in hypertensive patients with left ventricular hypertrophy. losartan is indicated to reduce the risk of cardiovascular morbidity and mortality as measured by the combined incidence of cardiovascular death stroke and myocardial infarction in hypertensive patients with left ventricular hypertrophy. the benefit of losartan on the primary deposite endpoi

ישראל - עברית - Ministry of Health

dexcel pharma technologies ltd - losartan potassium - טבליה - losartan potassium 50 mg - losartan - losartan - hypertension: losardex is indicated for the treatment of hypertension. heart failure: losardex is indicated for the treatment of heart failure (nyha ii and iii) usually in addition to diuretics and/or digitalis if use of an ace inhibitor is not appropriate. switching patients with heart failure who are stable on an ace inhibitor to losardex is not recommended. renal protection in type-2 diabetic patients with proteinuria: losardex is indicated to delay the progression of renal disease as measured by a reduction in the combined incidence of doubling of serum creatinine end stage renal disease (need for dialysis or renal transplantation) or death and to reduce proteinuria. reduction in the risk of cardiovascular morbidity and mortality in hypertensive patients with left ventricular hypertrophy. losardex is indicated to reduce the risk of cardiovascular morbidity and mortality as measured by the combined incidence of cardiovascular death stroke and myocardial infarction in hypertensive patients with left ventric

ישראל - עברית - Ministry of Health

dexcel pharma technologies ltd - losartan potassium - טבליה - losartan potassium 50 mg - losartan - losartan - hypertension: losardex is indicated for the treatment of hypertension. heart failure: losardex is indicated for the treatment of heart failure (nyha ii and iii) usually in addition to diuretics and/or digitalis if use of an ace inhibitor is not appropriate. switching patients with heart failure who are stable on an ace inhibitor to losardex is not recommended. renal protection in type-2 diabetic patients with proteinuria: losardex is indicated to delay the progression of renal disease as measured by a reduction in the combined incidence of doubling of serum creatinine end stage renal disease (need for dialysis or renal transplantation) or death and to reduce proteinuria. reduction in the risk of cardiovascular morbidity and mortality in hypertensive patients with left ventricular hypertrophy. losardex is indicated to reduce the risk of cardiovascular morbidity and mortality as measured by the combined incidence of cardiovascular death stroke and myocardial infarction in hypertensive patients with left ventric

ישראל - עברית - Ministry of Health

dexcel pharma technologies ltd - losartan potassium - קפליות - losartan potassium 100 mg - losartan - losartan - hypertension. losardex is indicated for the treatment of heart failure (nyha ii and iii) usually in addition to diuretics and/or digitalis if use of an ace inhibitor is not appropriate. switching patients with heart failure who are stable on an ace inhibitor to losardex is not recommended. renal protection in type-2 diabetic patients with proteinuria: losardex is indicated to delay the progression of renal disease as measured by a reduction in the combined incidence of doubling of serum creatinine end stage renal disease (need for dialysis or renal transplantation) or death and to reduce proteinuria. reduction in the risk of cardiovascular morbidity and mortality in hypertensive patients with left ventricular hypertrophy. losardex is indicated to reduce the risk of cardiovascular morbidity and mortality as measured by the combined incidence of cardiovascular death stroke and myocardial infarction in hypertensive patients with left ventricular hypertrophy. the benefit of losardex on the primary deposite endpoi

ישראל - עברית - Ministry of Health

dexcel pharma technologies ltd - losartan potassium - קפליות - losartan potassium 100 mg - losartan - losartan - hypertension. losardex is indicated for the treatment of heart failure (nyha ii and iii) usually in addition to diuretics and/or digitalis if use of an ace inhibitor is not appropriate. switching patients with heart failure who are stable on an ace inhibitor to losardex is not recommended.renal protection in type-2 diabetic patients with proteinuria: losardex is indicated to delay the progression of renal disease as measured by a reduction in the combined incidence of doubling of serum creatinine end stage renal disease (need for dialysis or renal transplantation) or death and to reduce proteinuria. reduction in the risk of cardiovascular morbidity and mortality in hypertensive patients with left ventricular hypertrophy. losardex is indicated to reduce the risk of cardiovascular morbidity and mortality as measured by the combined incidence of cardiovascular death stroke and myocardial infarction in hypertensive patients with left ventricular hypertrophy. the benefit of losardex on the primary deposite endpoin

ישראל - עברית - Ministry of Health

cts chemical industries ltd, israel - losartan potassium - טבליה - losartan potassium 50 mg - losartan - losartan - hypertension: losartan indicated for the treatment of heart failure ( nyha ii and iii) usually in addition to diuretics and/or digitalis if use of an ace inhibitor is not appropriate.switching patients with heart failure who are stable on an ace inhibitor to losartan is not recommended. renal protection in type - 2 diabetic patients with proteinuria: losartan indicated to delay the progression of renal disease as measured by a reduction in the combined incidence of doubling of serum creatinine end stage renal disease ( need for dialysis or renal transplantation) or death and to reduce proteinuria.reduction in the risk of cardiovascular morbidity and mortality in hypertensive patients with left ventricular hypertrphy. losartan is indicated to reduce the risk of cardiovascular morbidity and mortality as measured by the combined incidence of cardiovascular death stroke and myocardial infarction in hypertensive patients with left ventricular hypertrophy. the benefit of losartan on the primary composite end point

ישראל - עברית - Ministry of Health

bioavenir ltd - losartan as potassium 50 mg - tablets - losartan - hypertension: losartan is indicated for the treatment of heart failure ( nyha ii and iii) usually in addition to diuretics and/or digitalis if use of an ace inhibitor is not appropriate. switching patients with heart failure who are stable on an ace inhibitor to tiasar is not recommended. renal protection in type - 2 diabetic patients with proteinuria: losartan is indicated to delay the progression of renal disease as measured by a reduction in the combined incidence of doubling of serum creatinine end stage renal disease ( need for dialysis or renal transplantation) or death and to reduce proteinuria. reduction in the risk of cardiovascular morbidity and mortality in hypertensive patients with left ventricular hypertrphy. losartan is indicated to reduce the risk of cardiovascular morbidity and mortality as measured by the combined incidence of cardiovascular death stroke and myocardial infarction in hypertensive patients with left ventricular hypertrphy. the benefit of tiasar on the primary deposite end poin

ישראל - עברית - Ministry of Health

bioavenir ltd - losartan as potassium 100 mg - tablets - losartan - hypertension: losartan is indicated for the treatment of heart failure ( nyha ii and iii) usually in addition to diuretics and/or digitalis if use of an ace inhibitor is not appropriate. switching patients with heart failure who are stable on an ace inhibitor to tiasar is not recommended. renal protection in type - 2 diabetic patients with proteinuria: losartan is indicated to delay the progression of renal disease as measured by a reduction in the combined incidence of doubling of serum creatinine end stage renal disease ( need for dialysis or renal transplantation) or death and to reduce proteinuria. reduction in the risk of cardiovascular morbidity and mortality in hypertensive patients with left ventricular hypertrphy. losartan is indicated to reduce the risk of cardiovascular morbidity and mortality as measured by the combined incidence of cardiovascular death stroke and myocardial infarction in hypertensive patients with left ventricular hypertrphy. the benefit of tiasar on the primary deposite end poin

ישראל - עברית - Ministry of Health

glaxo smith kline (israel) ltd - zidovudine - תמיסה לאינפוזיה - zidovudine 200 mg / 20 ml - zidovudine - zidovudine - retrovir iv for infusion is indicated for the short term management of serious manifestations of human immunodeficiency virus (hiv) infection in patients with acquired immuno deficiency syndrome (aids) or aids related complex (arc) who are unable to take retrovir oral formulations.

ישראל - עברית - Ministry of Health

inovamed pharma ltd, israel - carbidopa; entacapone; levodopa - טבליות מצופות פילם - levodopa 100 mg; carbidopa 25 mg; entacapone 200 mg - levodopa - levodopa - treatment of patients with parkinson's disease and end-of-dose motor fluctuations not stabilised on levodopa/dopa decarboxylase (ddc) inhibitor treatment.